{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:16:30Z","timestamp":1787318190600,"version":"build-2736575974"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin\u2010producing beta\u2010cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin\u2010independent mechanisms and to partially mitigate the adverse effects associated with long\u2010term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short\u2010 and long\u2010term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin\u2010glucose\u2010dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.<\/jats:p>","DOI":"10.1002\/psp4.12956","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T07:55:41Z","timestamp":1678694141000},"page":"831-841","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A mechanistic modeling platform of\n                    <scp>SGLT2<\/scp>\n                    inhibition: Implications for type 1 diabetes"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-0811","authenticated-orcid":false,"given":"Victor","family":"Sokolov","sequence":"first","affiliation":[{"name":"M&amp;S Decisions  Moscow Russia"},{"name":"STU \u201cSirius\u201d  Sochi Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9715-0931","authenticated-orcid":false,"given":"Tatiana","family":"Yakovleva","sequence":"additional","affiliation":[{"name":"M&amp;S Decisions  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-8350","authenticated-orcid":false,"given":"Leonid","family":"Stolbov","sequence":"additional","affiliation":[{"name":"M&amp;S Decisions  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-8913","authenticated-orcid":false,"given":"Robert C.","family":"Penland","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boulton","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Parkinson","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_2_10_3_1","unstructured":"American Diabetes Association.Statistics about diabetes.2017. Available at:https:\/\/diabetes.org\/about\u2010us\/statistics\/about\u2010diabetes. Accessed 19 January 2023."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1771047"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0078"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.07.2300"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1519"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.30"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2062"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13858"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007304457"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007302168"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009341185"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-012-9289-6"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14305"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.2.426"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.270"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.899"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1612"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.5.801"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.6.1049"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0299"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2008.00355.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01168.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03149.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815573865"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.8.1279"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12856"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.07.005"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.01100.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13195"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.5.644"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.11.004"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2006.0035"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3087"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262949"},{"key":"e_1_2_10_43_1","unstructured":"AstraZeneca.A multicenter randomized double\u2010blind placebo\u2010controlled parallel group phase 3 study to evaluate the efficacy and safety of dapagliflozin as an add\u2010on to insulin therapy in subjects with type 1 diabetes mellitus.2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268214. Accessed 19 January 2023."},{"key":"e_1_2_10_44_1","unstructured":"AstraZeneca.A multicenter randomized double\u2010blind placebo\u2010controlled parallel group phase 3 study to evaluate the efficacy and safety of dapagliflozin as an add\u2010on to insulin therapy in subjects with type 1 diabetes mellitus \u2010 study two.2019. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02460978. Accessed 19 January 2023."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2008.04.011"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/152091502320798312"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.90295.2008"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08193-8"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13664"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040485"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.575789"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1410"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12956","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:06:20Z","timestamp":1694876780000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/psp4.12956"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12956","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}